OLEPTRO (trazodone hydrochloride) by Mthera Pharma is trazodone’s antidepressant action is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the cns. First approved in 2010.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
OLEPTRO is an extended-release oral tablet formulation of trazodone hydrochloride, a serotonergic antidepressant approved in 2010. It treats major depressive disorder through dual mechanisms: selective serotonin reuptake inhibition and 5HT2 receptor antagonism, though the precise interplay of these actions remains incompletely understood. The product is a small-molecule NDA indicated for depression in adult patients.
With loss of exclusivity approaching in 2029, OLEPTRO faces imminent generic competition and will require defensive commercial strategies to retain market share.
trazodone’s antidepressant action is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS. Trazodone is both a selective serotonin reuptake inhibitor (SSRI) and a 5HT2 receptor antagonist and the net result of this action on serotonergic…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PK Study of Diet Effect of Trazodone Hydrochloride Prolonged-Released Tablets in Healthy Chinese
PK Study of Multi-dose Trazodone Hydrochloride Prolonged-released Tablets in Healthy Chinese
A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression
Worked on OLEPTRO at Mthera Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LOE in ~3 years — strategic planning for patent cliff underway
With zero currently linked job openings, OLEPTRO represents a niche career opportunity in a mature, LOE-stage franchise. Roles will focus on defensive commercialization, payer management, and market preservation rather than growth or innovation.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo